Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q92600
UPID:
CNOT9_HUMAN
Alternative names:
Cell differentiation protein RQCD1 homolog
Alternative UPACC:
Q92600; B2RPI0; B5MDQ4; B7Z1E5; Q96IX4
Background:
CCR4-NOT transcription complex subunit 9, also known as Cell differentiation protein RQCD1 homolog, plays a pivotal role in mRNA deadenylation, a process crucial for mRNA degradation and regulation. It is a component of the CCR4-NOT complex, integral to mRNA degradation, miRNA-mediated repression, and transcription regulation. This protein's ability to bind oligonucleotides, albeit not poly-A, and its involvement in MYB- and JUN-dependent transcription down-regulation highlight its multifunctionality in cellular processes.
Therapeutic significance:
Understanding the role of CCR4-NOT transcription complex subunit 9 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as mRNA degradation and transcription regulation makes it a promising target for drug discovery, aiming to modulate gene expression in various diseases.